A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 5, 2014, Pages 1039-1046

  Mateo, J ^a   Berlin, J ^b   De Bono, J S ^a   Cohen, R B ^c   Keedy, V ^b   Mugundu, G ^d   Zhang, Lianglin ^d   Abbattista, A ^d   Davis, C ^d   Gallo Stampino, C ^d   Borghaei, H ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d PFIZER INC   (United States)

Author keywords

ADCC; Angiogenesis; Antibody; First in human; Integrin; Phase I trial

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MONOCLONAL ANTIBODY; PF 04605412; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; PF-04605412;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; FLUSHING; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HALF LIFE TIME; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPERTENSION; HYPONATREMIA; HYPOTENSION; IMMUNOGENICITY; INFUSION RELATED REACTION; LYMPHOCYTE SUBPOPULATION; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NAUSEA; PLASMA VOLUME; SIDE EFFECT; SOLID TUMOR; TACHYCARDIA; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; VOLUME OF DISTRIBUTION; VOMITING; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FLUSHING; HUMANS; HYPOTENSION; INFUSIONS, INTRAVENOUS; INTEGRIN ALPHA5BETA1; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; NEOPLASMS; TREATMENT OUTCOME;

EID: 84919727111     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2576-8     Document Type: Article

References (27)

1. Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines in their roles as major adhesion receptors, integrins. Cell 110:673-687
2. Miranti CK, Brugge JS (2002) Sensing the environment: a historical perspective on integrin signal transduction. Nat Cell Biol 4:E83-E90
3. Wennerberg K, Lohikangas L, Gullberg D, Pfaff M, Johansson S, Fässler R (1996) Beta 1 integrin-dependent and -independent polymerization of fibronectin. J Cell Biol 132:227-238
4. Bauer JS, Varner J, Schreiner C, Kornberg L, Nicholas R, Juliano RL (1993) Functional role of the cytoplasmic domain of the integrin alpha 5 subunit. J Cell Biol 122:209-221
5. Jin H, Varner J (2004) Integrins: roles in cancer development and as treatment targets. Br J Cancer [Internet] 90:561-565
6. Muschler JL, Horwitz AF (1991) Down-regulation of the chicken alpha 5 beta 1 integrin fibronectin receptor during development. Development 113:327-337
7. Yang JT, Rayburn H, Hynes RO (1993) Embryonic mesodermal defects in alpha 5 integrin-deficient mice. Development 119:1093-1105
8. Francis SE, Goh KL, Hodivala-Dilke K, Bader BL, Stark M, Davidson D et al (2002) Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler Thromb Vasc Biol 1(22):927-933
9. Kim S, Bell K, Mousa SA, Varner JA (2000) Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 156:1345-1362
10. Adil MM, Levine RM, Kokkoli E (2014) Increasing cancer-specific gene expression by targeting overexpressed α5β1 integrin and upregulated transcriptional activity of NF-κB. Mol Pharm 11(3):849-858
11. Ricart AD, Tolcher AW, Liu G, Holen K, Schwartz G, Albertini M et al (2008) Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 1(14):7924-7929
12. Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT et al (2011) A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 1(121):273-279
13. Besse B, Tsao LC, Chao DT, Fang Y, Soria J-C, Almokadem S et al (2013) Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 24:90-96
14. Zhang L, Stock J, Elliot M, Chen E, Nguyen T, Wong A et al (2013) Abstract 2336: assessment of mechanisms of action (MOAs) of the Fc-engineered integrin α5β1 targeting antibody PF-04605412 in human integrin α5 knock-in mice. Cancer Res. p. abstract 2336
15. Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E et al (2005) Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol 20(23):474-481
16. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV (1998) Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A 20(95):652-656
17. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443-446
18. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833
19. Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J et al (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 10(25):5616-5623
20. Ferris RL, Jaffee EM, Ferrone S (2010) Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 1(28):4390-4399
21. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M et al (2010) Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 1(28):1124-1130
22. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 1(20):719-726
23. Thompson LM, Eckmann K, Boster BL, Hess KR, Michaud LB, Esteva FJ et al (2014) Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving Trastuzumab. Oncol 19(3):228-234
24. Ricart AD, Tolcher AW, Liu G, Holen K, Schwartz G, Albertini M et al (2008) Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 1(14):7924-7929
25. Cook-Burns N (2001) Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 61(Suppl 2):58-66
26. Luu KT, Bergqvist S, Chen E, Hu-lowe D, Kraynov E (2012) A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition. J Pharmacol Exp Ther 341:702-708
27. Gibiansky L, Gibiansky E (2014) Target-mediated drug disposition model and its approximations for antibody-drug conjugates. J Pharmacokinet Pharmacodyn 41:35-47